Hybridization of antimicrobial oxazolidinones with commercial drugs: A fight against the "superbugs".

Publisher: Wiley-Liss Country of Publication: United States NLM ID: 8204468 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1098-2299 (Electronic) Linking ISSN: 02724391 NLM ISO Abbreviation: Drug Dev Res Subsets: MEDLINE

Publication: New York Ny : Wiley-Liss
Original Publication: New York : Alan R. Liss, c1981-

Oxazolidinones*/pharmacology ; Oxazolidinones*/therapeutic use ; Anti-Infective Agents*/pharmacology ; Anti-Infective Agents*/therapeutic use; Anti-Bacterial Agents/pharmacology

Antimicrobial resistance caused by the emergence of antibiotic-resistant microbes, termed as "superbugs," poses a grave healthcare concern in the contemporary era. Though this phenomenon is natural, an incessant use of antibiotics due to their unregulated over-the-counter availability, and a lack of compliance with the legislation seem to be major contributing factors. This phenomenon has further complicated the treatment of common infectious diseases thereby leading to prolonged illness, disability, and even death. In addition, a sizeable impact on the healthcare cost is met due to a prolonged stay at the medical facilities to receive an intensive care. Overall, the gains of "Millennium Development Goals" and the accomplishment of Sustainable Development Goals are at risk due to the emerging antimicrobial resistance. Since an early identification and development of novel antibiotic classes that evade antimicrobial resistance appears improbable, the strategy of hybridization of the existing antibiotics with efficacious pharmacophores and drug molecules with a different mechanism of antimicrobial action can be a silver lining for the management of superbugs. In this regard, we aim to provide a perspective for the applicability of the hybridization of oxazolidinone class of antibiotics with other drugs for evading antimicrobial resistance.
(© 2023 Wiley Periodicals LLC.)

Alfei, S., & Schito, A. M. (2022). β-Lactam antibiotics and β-lactamase enzymes inhibitors, part 2: our limited resources. Pharmaceuticals, 15, 476.
Faazil, S., Malik, M. S., Ahmed, S. A., Alsantali, R. I., Yedla, P., Alsharif, M. A., Shaikh, I. N., & Kamal, A. (2022). Novel linezolid-based oxazolidinones as potent anticandidiasis and antitubercular agents. Bioorganic Chemistry, 126, 105869.
Gan, W. C., Ng, H. F., & Ngeow, Y. F. (2023). Mechanism of linezolid resistance in mycobacteria. Pharmaceuticals (MDPI), 16, Article 784.
Gerding, D. N., Cornely, O. A., Grill, S., Kracker, H., Marrast, A. C., Nord, C. E., Talbot, G. H., Buitrago, M., Gheorghe Diaconescu, I., Murta de Oliveira, C., Preotescu, L., Pullman, J., Louie, T. J., & Wilcox, M. H. (2019). Cadazolid for the treatment of Clostridium difficile infection: Results of two double-blind, placebo-controlled, non-inferiority, randomised phase 3 trials. The Lancet Infectious Diseases, 19, 265-274.
Liu, L., Shao, L., Li, J., Cui, H., Li, B., Zhou, X., Lv, P., & Zhang, J. (2019). Synthesis, antibacterial activities, mode of action, and acute toxicity studies of new oxazolidinone-fluoroquinolone hybrids. Molecules, 24, 1641.
Liu, R., Miller, P. A., Vakulenko, S. B., Stewart, N. K., Boggess, W. C., & Miller, M. J. (2018). A synthetic dual drug sideromycin induces gram-negative bacteria to commit suicide with a gram-positive antibiotic. Journal of Medicinal Chemistry, 61, 3845-3854.
Lungu, I.-A., Moldovan, O.-L., Biriș, V., & Rusu, A. (2022). Fluoroquinolones hybrid molecules as promising antibacterial agents in the fight against antibacterial resistance. Pharmaceutics, 14, 1749.
Malik, M. S., Faazil, S., Alsharif, M. A., Sajid Jamal, Q. M., Al-Fahemi, J. H., Banerjee, A., Chattopadhyay, A., Pal, S. K., Kamal, A., & Ahmed, S. A. (2023). Antibacterial properties and computational insights of potent novel linezolid-based oxazolidinones. Pharmaceuticals, 16, 516.
Murray, C., Ikuta, K. S., Sharara, F., Swetschinski, L., Robles Aguilar, G., Gray, A., Han, C., Bisignano, C., Rao, P., Wool, E., Johnson, S. C., Browne, A. J., Chipeta, M. G., Fell, F., Hackett, S., Haines-Woodhouse, G., Kashef Hamadani, B. H., Kumaran, E., McManigal, B., … Tasak, N. (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. The Lancet, 399, 629-655.
Patel, K. B., & Kumari, P. (2022). A review: Structure activity relationship and antibacterial activities of quinolone-based hybrids. Journal of Molecular Structure, 1268, Article 133634.
Prasher, P., Mall, T., & Sharma, M. (2023). Cyclic carbamates in medicine: A clinical perspective. Drug Development Research, 84, 397-405.
Rakesh, D., Sun, D., Lee, R. B., Tangallapally, R. P., & Lee, R. E. (2009). Synthesis, optimization, and structure-activity relationships of 3,5-disubstituted isoxazolines as new anti-tuberculosis agents. European Journal of Medicinal Chemistry, 44, 460-472.
Rakesh, D., Bruhn, D. F., Scherman, M. S., Singh, A. P., Yang, L., Liu, J., Lenaerts, A. J., & Lee, R. E. (2016). Synthesis and evaluation of pretomanid (PA-824) oxazolidinone hybrids. Bioorganic & Medicinal Chemistry Letters, 26, 388-391.
Rayner, B., Verderosa, A. D., Ferro, V., & Blaskovich, M. A. T. (2023). Siderophore conjugates to combat antibiotic-resistant bacteria. RSC Medicinal Chemistry, 14, 800-822.
Scaiola, A., Leibundgut, M., Boehringer, D., Caspers, P., Bur, D., Locher, H. H., Rueedi, G., & Ritz, D. (2019). Structural basis of translation inhibition by cadazolid, a novel quinoxolidinone antibiotic. Scientific Reports, 9, 5634.
Yuan, S., Shen, D.-D., Bai, Y.-R., Zhang, M., Zhou, T., Sun, C., Zhou, L., Wang, S.-Q., & Liu, H.-M. (2023) Oxazolidinone: a promising scaffold for the development of antibacterial drugs. European Journal of Medicinal Chemistry. 250, 115239.

Keywords: amtimicrobial resistance; antibiotics; cyclic carbamates; hybridization; oxazolidinones

0 (Oxazolidinones)
0 (Anti-Infective Agents)
0 (Anti-Bacterial Agents)

Date Created: 20230816 Date Completed: 20231110 Latest Revision: 20231114

20231114

10.1002/ddr.22107

37583273